Eli Lilly's (LLY) ramucirumab drug for gastric cancer meets its main goal of improving overall...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly's (LLY) ramucirumab drug for gastric cancer meets its main goal of improving overall survival in a Phase III study, with the treatment also increasing survival without the cancer worsening. Shares +1.8% premarket. (PR)